Sight Diagnostics Company

"Advanced Blood Diagnostics Platform."

Sight Diagnostics uses advanced computer-vision and machine-learning technology in the field of blood diagnostics. The company’s initial product, the Parasight platform, is a highly accurate, easy-to-use device for diagnosing malaria.
Sight Diagnostics is also applying its technology to the complete blood count (CBC) market, developing a point-of-care CBC platform that will provide a five-point differential blood count for use in doctors’ offices and emergency medical centers.
Beyond its malaria and CBC platforms, the company’s computer-vision technology has the potential to unlock advanced diagnostic approaches to numerous additional diseases and provide patients with accurate and inexpensive testing.
In December 2019, the company received FDA 510(k) clearance for its OLO analyzer, a device that performs blood tests and provides lab-grade results in minutes. Tests include the complete blood count (CBC) panel, which comprises the most common and useful tests conducted by medical professionals.

Combating Coronavirus Pandemic:
Sight Diagnostics's solution helps address the Coronavirus Pandemic. Sight Diagnostics has deployed its safe blood test technology for coronavirus patients at Israel’s Sheba Medical Center. The hospital is using its OLO compact blood analyzer for rapid, lab-grade complete blood count results in its special lab.
Technology: COVID Treatment
Industry: AI for Research and Healthcare
Headquarters: Israel
Founded Date: 2010
Employees Number: N/A
Funding Status: N/A

Visit Website
Register and Claim Ownership